Li-Xiang Fu

May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension

P. López-Jaramillo, D. Prabhakaran, E. O’Brien, 2019, European heart journal.

Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells

Y. Wen, Zhe-Sheng Chen, Dong-Hua Yang, 2017, Oncotarget.

The association of serum uric acid with metabolic syndrome and its components—From a single‐clinical centre in China

C. Liu, Li-Xiang Fu, Tingting Wang, 2020, International journal of clinical practice.

The epigallocatechin gallate derivative Y6 inhibits human hepatocellular carcinoma by inhibiting angiogenesis in MAPK/ERK1/2 and PI3K/AKT/ HIF-1α/VEGF dependent pathways.

Yan-yan Chen, Run-Li Chen, G. Liang, 2020, Journal of ethnopharmacology.

The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.

Yan-yan Chen, G. Liang, Li-Xiang Fu, 2020, Journal of ethnopharmacology.

Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients

Li-Xiang Fu, Tingting Wang, Jian Xu, 2020, International journal of clinical practice.